Guerrero, Angel L.
Negro, Andrea
Ryvlin, Philippe
Skorobogatykh, Kirill
Sanchez-De La Rosa, Rainel
Israel-Willner, Heike
Sundal, Christina
MacGregor, E. Anne
Funding for this research was provided by:
Novartis
Article History
Received: 16 September 2020
Accepted: 23 February 2021
First Online: 20 March 2021
Declarations
:
: Ethics Committee approval was not applicable in this survey because its objective was to understand chronic migraine patients’ management in the primary care setting. There was no need to collect any type of patient data or information, hence the approval of an Ethics Committee or patient informed consent was not required. All survey participants gave their written consent.
: Not applicable.
: Dr. Guerrero reports personal fees from Novartis during the conduct of the study, and personal fees from Allergan, Exeltis, Eli Lilly and Teva outside the submitted work.Dr. Negro reports personal fees from Novartis during the conduct of the study, and personal fees from Allergan, Eli Lilly and Teva, outside the submitted work.Dr. Ryvlin reports personal fees from Novartis, during the conduct of the study and personal fees from Eli Lilly and Novartis outside the submitted work.Dr. Skorobogatykh reports personal fees from Novartis during the conduct of the study; and personal fees from Novartis and Teva, outside the submitted work.Dr. Rainel Sanchez-De la Rosa reports he is an employee and stakeholder of Novartis Pharma AG.Dr. Israel-Willner has nothing to disclose.Dr Sundal reports personal fees from Novartis, during the conduct of the study and personal fees from Allergan, outside the submitted work.Dr. MacGregor reports personal fees from Novartis, during the conduct of the study; personal fees from Eli Lilly, outside the submitted work; and Co-author of Aids to management of headache disorders in primary care (2nd edition): On behalf of the European Headache Federation and Lifting the Burden: The Global Campaign against Headache. Vol. 20, Journal of Headache and Pain. The Journal of Headache and Pain; 2019.